前列腺癌患者接受[225Ac]Ac-PSMA放射性药物治疗的PET预后预测
结果显示SUVmean可预测早期进展并延长无进展生存期,PSMA-TLQ与总生存期相关。
要点
- 治疗前[18F]F-PSMA-1007 PET/CT的SUVmean可预测早期进展和较短的无进展生存期。
- PSMA-TLQ与总生存期相关,低PSMA-TLQ患者中位总生存期更长。
- 治疗前PSMA PET定量可能优化靶向α放射性药物治疗的患者选择。
核心结论
- 在计划接受[225Ac]Ac-PSMA-I&T放射性药物治疗的患者中,治疗前[18F]F-PSMA-1007 PET/CT的SUVmean可预测早期治疗反应,识别易发生早期进展和较短无进展生存期的个体。
- PSMA-TLQ与总生存期相关,治疗前PSMA PET定量可能优化靶向α放射性药物治疗的患者选择。
研究设计与样本
- 治疗前[18F]F-PSMA-1007 PET/CT上分割所有转移灶,评估平均SUVmax、SUVmean、PSMA肿瘤总体积(PSMA-TV)和PSMA总病灶商(PSMA-TLQ,定义为PSMA-TV除以SUVmean)。
- PET参数与2周期[225Ac]Ac-PSMA-I&T放射性药物治疗后PSA相对变化相关,并探索对早期进展、无进展生存期和总生存期的预测价值。
主要发现
- SUVmax(r=-0.42,P=0.031)和SUVmean(r=-0.4,P=0.046)与2周期后PSA变化显著相关,PSMA-TV(P=0.51)和PSMA-TLQ(P=0.83)无显著相关。
- SUVmax(比值比0.769,P=0.032)和SUVmean(比值比0.427,P=0.041)可预测早期进展。
- SUVmean是无进展生存期延长的最强预测因子(风险比0.501,P=0.006),SUVmax也趋于显著(风险比0.914,P=0.054)。
- 高SUVmean患者中位无进展生存期134天,低SUVmean患者39天(风险比0.369,P=0.041);PSMA-TLQ(风险比1.007,P=0.027)和PSMA-TV(风险比1.001,P=0.037)可预测总生存期;低PSMA-TLQ患者中位总生存期375天,高PSMA-TLQ患者148天(风险比2.84,P=0.043)。
关键数值与推荐
- 早期进展定义为2周期后PSA升高超过25%或根据RECIP 1.0判定为进展。
临床怎么用
- 对于计划接受[225Ac]Ac-PSMA-I&T放射性药物治疗的转移性去势抵抗性前列腺癌患者,治疗前[18F]F-PSMA-1007 PET/CT的SUVmean可用于识别易发生早期进展和较短无进展生存期的个体。
- PSMA-TLQ可提供总生存期预后信息,辅助患者选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
225Ac-labeled prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (RPT) has emerged as a promising treatment option in advanced metastatic castration-resistant prostate cancer. We aimed to identify predictors for outcome including established clinical and PSMA-directed imaging parameters at baseline. Methods: Twenty-six patients with metastatic castration-resistant prostate cancer who were receiving [225Ac]Ac-PSMA-I&T RPT were included in this retrospective monocentric study. In each patient, all metastases on pretherapeutic [18F]F-PSMA-1007 PET/CT were segmented, enabling assessment of averaged SUVmax, SUVmean, as well as summed PSMA tumor volume (PSMA-TV) and PSMA-total lesion quotient (PSMA-TLQ; defined as PSMA-TV divided by SUVmean). PET parameters were then correlated with the relative prostate-specific antigen (PSA) change after 2 cycles of [225Ac]Ac-PSMA-I&T RPT. In addition, the predictive values for early progressive disease (PD; defined as a PSA increase of more than 25% or PD according to RECIP 1.0) after 2 cycles, progression-free survival (PFS), and overall survival (OS) were explored. Results: SUVmax (r = -0.42, P = 0.031) and SUVmean (r = -0.4, P = 0.046) correlated significantly with PSA change after 2 cycles, but PSMA-TV (P = 0.51) and PSMA-TLQ (P = 0.83) did not. Eleven patients (42%) demonstrated early PD. SUVmax (odds ratio, 0.769; P = 0.032) and SUVmean (odds ratio, 0.427; P = 0.041) were predictive for early PD. SUVmean emerged as the strongest predictor for prolonged PFS (hazard ratio [HR], 0.501; P = 0.006) with SUVmax also trending toward significance (HR, 0.914; P = 0.054). Patients with a high SUVmean achieved a longer median PFS of 134 d compared with 39 d in patients with low SUVmean (HR, 0.369; P = 0.041). PSMA-TLQ (HR, 1.007; P = 0.027) and PSMA-TV (HR, 1.001; P = 0.037) were predictive for OS. Patients with a low PSMA-TLQ (reflecting low PSMA-TV in combination with high SUVmean) achieved a longer median OS of 375 d compared with 148 d in patients with high PSMA-TLQ (HR, 2.84; P = 0.043). Conclusion: In patients scheduled for [225Ac]Ac-PSMA-I&T RPT, SUVmean on pretherapeutic [18F]F-PSMA-1007 PET/CT is predictive for early treatment response by identifying individuals prone to early PD and shorter PFS. In addition, PSMA-TLQ is associated with OS. As such, pretherapeutic PSMA PET-based quantification may optimize patient selection for targeted α-RPT.
引用
- Widjaja L, Siegmund SC, Gildehaus FJ, et al. PET-Based Outcome Prediction in Patients with Prostate Cancer Scheduled for [225Ac]Ac-PSMA Radiopharmaceutical Therapy. J Nucl Med. 2026. PMID: 41611481. doi:10.2967/jnumed.125.270677
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。